By Billy Candra 
A pivotal, federally funded clinical trial, the first of its kind, has achieved a significant breakthrough in breast cancer management, demonstrating the feasibility of identifying breast cancer survivors at elevated risk of recurrence due to dormant cancer cells and effectively eliminating these cells using existing, repurposed drugs. The landmark research, spearheaded by scientists from the Abramson Cancer Center at the University of Pennsylvania and Penn’s Perelman School of Medicine, was formally unveiled today in the prestigious journal Nature Medicine. This advancement represents a potential paradigm shift, moving beyond the current "wait and see" approach to proactive intervention for millions of survivors globally.
The Persistent Shadow of Recurrence: A Global Health Challenge
Despite remarkable strides in early detection, surgical techniques, radiation therapy, chemotherapy, and targeted treatments, breast cancer recurrence remains a formidable challenge in oncology. While overall survival rates have steadily improved, the grim reality is that when breast cancer relapses after initial treatment, it is often incurable, transforming into a metastatic disease that necessitates continuous, indefinite treatment without the prospect of complete eradication. Approximately 30% of breast cancer survivors, both women and men, eventually experience a recurrence. This statistic translates to hundreds of thousands of individuals worldwide annually facing the devastating news that their cancer has returned, often with a more aggressive trajectory.
The timing of recurrence varies significantly depending on the biological subtype of the cancer. Aggressive forms such as triple-negative breast cancer (TNBC) and HER2-positive (HER2+) breast cancer tend to recur within a few years of initial treatment. In contrast, estrogen receptor-positive (ER+) breast cancer, the most common subtype, can lie dormant for much longer periods, sometimes recurring decades after the initial diagnosis and successful treatment. This unpredictable nature of relapse creates immense psychological distress for survivors, a constant "sword of Damocles" hanging over their lives, even long after they have celebrated the completion of primary therapy. Until now, clinicians lacked a reliable method to identify these high-risk individuals in real-time or to intervene with a preventive treatment before recurrence manifests as an incurable disease.
The financial burden associated with managing metastatic breast cancer is also substantial, placing immense strain on healthcare systems and individual patients. The ability to prevent recurrence could not only save lives and improve quality of life but also significantly reduce long-term healthcare costs.
Unmasking the "Sleeper Cells": The Enigma of Minimal Residual Disease (MRD)
The foundation of this groundbreaking study lies in understanding the elusive nature of dormant tumor cells, often referred to as "sleeper cells" or, more scientifically, minimal residual disease (MRD). These are cancer cells that survive initial treatments but do not actively proliferate. Instead, they enter a quiescent state, scattered throughout the body, often residing in distant organs like the bone marrow, lungs, or liver. Because they are not actively dividing or forming visible tumors, they evade detection by standard imaging tests such as mammograms, CT scans, and PET scans, which primarily identify metabolically active or structurally apparent lesions.
The concept of MRD is not new to oncology, particularly in hematological malignancies like leukemia, where its detection has long guided treatment decisions. However, its application in solid tumors like breast cancer, especially for real-time risk stratification and intervention, has been far more challenging. Once these sleeper cells reactivate and begin to expand and circulate in the bloodstream, they can lead to the widespread dissemination of metastatic breast cancer. Patients found to harbor MRD are demonstrably at a higher risk of experiencing breast cancer recurrence and, consequently, have decreased overall survival rates.
Dr. Lewis Chodosh, MD, PhD, Chair of Cancer Biology and senior author of the study, has dedicated years to unraveling the mysteries of these dormant cells. His prior research laid crucial groundwork by identifying the specific molecular pathways that enable dormant tumor cells to survive in patients, sometimes for decades, without detection or causing symptoms. This fundamental understanding was critical to developing strategies for intervention. "Our research shows that this sleeper phase represents an opportunity to intervene and eradicate the dormant tumor cells before they have the chance to come back as aggressive, metastatic disease," Chodosh stated, highlighting the strategic window this discovery opens. He further emphasized a surprising insight: "Surprisingly, we’ve found that certain drugs that don’t work against actively growing cancers can be very effective against these sleeper cells. This tells us that the biology of dormant tumor cells is very different from active cancer cells." This differentiation in biological behavior and drug sensitivity is a cornerstone of the new treatment approach.
From Lab Bench to Bedside: Preclinical Foundations and Repurposed Therapeutics
The journey from understanding dormancy to clinically actionable treatment began with rigorous preclinical investigations. Dr. Chodosh’s team conducted a series of sophisticated experiments in mouse models of breast cancer. These studies were designed to meticulously dissect the underlying mechanisms that allow tumor cells to enter and maintain a dormant state. Their research identified two key cellular pathways critical for dormancy: autophagy and mTOR signaling.
Autophagy, a fundamental cellular process, is essentially the cell’s "self-eating" mechanism, recycling damaged organelles and proteins to maintain cellular homeostasis, especially under stress conditions like nutrient deprivation. For dormant cancer cells, autophagy can be a survival mechanism, allowing them to subsist in a low-energy state. The mTOR (mammalian target of rapamycin) pathway is another crucial regulator of cell growth, proliferation, and survival, playing a central role in sensing nutrient availability and energy status. By targeting these pathways, the researchers hypothesized they could disrupt the survival mechanisms of dormant cells without necessarily affecting actively proliferating cells, which rely on different metabolic programs.
In these preclinical studies, two different drugs, both already approved by the FDA for treating other medical conditions, were tested. These drugs were chosen precisely because they targeted the identified autophagy and mTOR signaling pathways. The results in mice were compelling: these repurposed drugs were able to effectively clear MRD, leading to significantly longer survival without any cancer recurrence. The success of these FDA-approved drugs in a preclinical setting immediately streamlined the path to human clinical trials, offering the advantages of known safety profiles and availability.
The CLEVER Clinical Trial: A New Paradigm in Prevention
Building on the robust preclinical data, Dr. Angela DeMichele, MD, MSCE, FASCO, the Mariann T. and Robert J. MacDonald Professor in Breast Cancer Research and the principal investigator of the clinical trial, led the effort to translate these findings into a human study. The Phase II CLEVER clinical trial was meticulously designed to identify and treat dormant cancer cells in breast cancer survivors.
The trial initiated a novel two-step process. First, breast cancer survivors who had completed their primary treatment within the last five years and had clear standard imaging scans were enrolled in a screening study. The crucial element of this screening was the search for dormant tumor cells in the participants’ bone marrow, a common sanctuary site for MRD. This innovative screening step allowed researchers to identify a specific subset of survivors who, despite appearing cancer-free by conventional measures, harbored these dangerous "sleeper cells" and were thus at higher risk of future recurrence.
If dormant tumor cells were detected, patients became eligible to enroll in the therapeutic arm of the Phase II CLEVER trial. This randomized trial assigned patients to receive one of two treatment regimens: either monotherapy with one of the two study drugs (the FDA-approved drugs identified in preclinical work) or combination therapy with both drugs. Participants received six cycles of treatment over several months.
The results from the 51 breast cancer survivors enrolled in CLEVER were remarkably positive. The existing drugs were able to clear dormant tumor cells from an impressive 80% of the study participants. The clinical benefit was equally striking: after a median follow-up period of 42 months (3.5 years), the three-year survival rate without any disease recurrence was above 90% in patients who received one drug, and a perfect 100% for patients who received both study drugs. Critically, only two patients on the entire study experienced a cancer recurrence during the follow-up period. This outcome stands in stark contrast to the historical 30% recurrence rate for breast cancer survivors.
"The lingering fear of cancer returning is something that hangs over many breast cancer survivors after they celebrate the end of treatment," Dr. DeMichele articulated, capturing the profound emotional impact of a cancer diagnosis. "Right now, we just don’t know when or if someone’s cancer will come back — that’s the problem we set out to solve. Our study shows that preventing recurrence by monitoring and targeting dormant tumor cells is a strategy that holds real promise, and I hope it ignites more research in this area." She added, "We want to be able to give patients a better option than ‘wait and see’ after they complete breast cancer treatment. We’re encouraged by these results that we’re on the right track."
Expert Perspectives and Broader Implications
The findings from the CLEVER trial represent a significant step forward in breast cancer management, offering a proactive strategy where previously none existed. The oncology community is likely to view these results with considerable optimism, recognizing the potential to fundamentally alter the post-treatment landscape for breast cancer survivors. Patient advocacy groups are also expected to welcome this development as a beacon of hope for reducing the anxiety and improving the long-term outcomes for those living beyond a breast cancer diagnosis.
The strategic advantage of using repurposed FDA-approved drugs cannot be overstated. Drug repurposing offers several benefits:
- Reduced Development Time and Cost: Since these drugs have already undergone extensive safety testing for other indications, the approval process for a new use is typically much faster and less expensive than developing a completely new molecular entity.
- Known Safety Profiles: Clinicians are already familiar with the side effect profiles and dosages of these medications, which facilitates their integration into clinical practice.
- Accessibility: Repurposed drugs are often generic and widely available, potentially making this preventive strategy more accessible and affordable for a broader patient population once fully validated.
This approach could inspire similar strategies across other cancer types where dormant cells contribute to recurrence, such as prostate, lung, and colorectal cancers, as well as melanoma. It underscores the importance of deeply understanding cancer cell biology, even in its quiescent states, to uncover new vulnerabilities.
Looking Ahead: Next Steps and Expanding the Horizon
While the results of the CLEVER trial are highly encouraging, it is a Phase II study involving a relatively small cohort of patients. To confirm and expand upon these promising findings, the Penn Medicine team is already actively enrolling patients in two larger, ongoing Phase II clinical trials: the ABBY clinical trial and the PALAVY clinical trial. These studies are available at multiple cancer centers across the country, aiming to validate the efficacy and safety of this approach in a more diverse and larger patient population. The successful interim outcomes data from the CLEVER study, which Dr. DeMichele previously reported at the European Society for Medical Oncology (ESMO) Congress 2023, further bolster confidence in the direction of this research.
The long-term vision is to integrate MRD screening and targeted prevention into standard breast cancer follow-up care. This would transform the current reactive model of treating recurrence into a proactive, personalized prevention strategy, offering survivors not just hope, but a tangible path to a cancer-free future. The implications extend beyond breast cancer, suggesting a future where identifying and eradicating dormant cancer cells could become a cornerstone of long-term cancer management across various malignancies.
This critical research was made possible through substantial financial backing from several key organizations, including the National Cancer Institute (R01CA208273) and the Department of Defense (BC160784). Additional crucial support was provided by philanthropic contributions and foundations such as the V Foundation, Breast Cancer Research Foundation, QVC "Shoes on Sale," Avon Foundation, and the Raynier Institute & Foundation. Such collaborative funding underscores the widespread recognition of the potential impact of this innovative research. Patients interested in learning more about these or other breast cancer clinical trials at Penn Medicine are encouraged to contact [email protected] for further information.
